Dimerix Ltd. and Fuso Pharmaceutical Industries Ltd. signed a license agreement for the development and commercialization of Dimerix’s phase III candidate, DMX-200, for the treatment of focal ...

The antibody-drug conjugate (ADC) arena continues to ring up deals, as Avenzo Therapeutics Inc. signed an exclusive license agreement with Duality Biotherapeutics Inc., whereby Avenzo will develop, ...

South Korea’s government continued to ramp up investment in its pharmaceutical and med-tech sector in 2025, including a 7.2% ...

Ophthalmic diseases specialist Oculis Holding AG announced positive phase II data showing its serum-glucose corticoid ...

Artificial intelligence (AI)-based models developed by a team of international researchers were able to identify ovarian ...

Small-cell lung cancer accounts for about 10%-15% of all lung cancers, yet its molecular pathogenesis remains largely ...

The device industry is extraordinarily dependent on administrative activity where Medicare coverage is concerned, and this ...

Altamira Therapeutics Ltd.’s nanoparticle-based delivery platform has been successfully tested for circular mRNA.

Already hot for years, antibody-drug conjugates (ADCs) continued to hold charm for the industry, sparking a number of sizable ...

The Asia Pacific med-tech market is projected to reach $140 billion in 2025 in value, growing roughly 5% per year, driven ...

Roche Holding AG kicked off the new year (again) with a potential $1 billion deal, including $80 million up front, for ...

The dengue virus (DENV) is a single-stranded RNA virus with increasing worldwide prevalence causing severe mosquito-borne viral infections. Therefore, effective strategies to prevent and treat DENV ...